| Voxelotor | Global Blood Theraps | ||
| 300 mg and 500 mg ; Tablet |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| None | None | ||
| OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. | |||
|
Yes
| |||
| Oxbryta | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| *** **** | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | ********* ********* ********* | ********* ********* ********* | *** ********* | **** ** *** **, **** | ********* ********* ********* | *** ********* (***** ******) |
| ***** ****** | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | ********* ********* ********* | ********* ********* ********* | *** ********* | **** ** *** **, **** | ********* ********* ********* | **** ** *** **, **** (***** ******) |
| ********* *** **** ******* *** *** ********** ** ********** | *********** ************ ********* *** ******* *** ***** *** ** ********** ****** *********** | ******* ********** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ | *********** ********** ** *** **** **** ** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ | *********** ************ ********* *** ******* *** ***** *** ** ********** ****** *********** | ****** ******** *** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ | *********** ********** ** *** **** **** ** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ | ****** ******** *** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ | *********** ************ ********* *** ******* *** ***** *** ** ********** ****** *********** | *:* ******* ** ****** ********** | *********** ********** ** *** **** **** ** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** **** | *** \ ********* | *** **, **** | ******* | **** | *** ****** *** **** |
| ***** ****** | *** \ ********* | *** **, **** | ******* | **** | *** ****** *** **** |
| Voxelotor | Global Blood Theraps | ||
| 300 mg ; Tablets for Oral Suspension |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
| None | None | ||
| OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. | |||
|
Yes
| |||
| Oxbryta | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| ***** ****** | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | ********* ********* ********* | *** ********* | **** ** *** **, **** | ********* ********* ********* | **** ** *** **, **** (***** ******) |
| ********* *** **** ******* *** *** ********** ** ********** | *********** ************ ********* *** ******* *** ***** *** ** ********** ****** *********** | *********** ********** ** *** **** **** ** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ | *********** ************ ********* *** ******* *** ***** *** ** ********** ****** *********** | ****** ******** *** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ | *********** ********** ** *** **** **** ** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ | ****** ******** *** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ | *********** ************ ********* *** ******* *** ***** *** ** ********** ****** *********** | *:* ******* ** ****** ********** | *********** ********** ** *** **** **** ** *-*******-*-((*-(*-*********-**-*******-*-**)*******-*-**)*******)************ |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** ****** | *** \ ********* | *** **, **** | ******* | **** | *** ****** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|